Arkolith/Insider Trading/VOR/Form 4

Kress Jean-Paul

CEO and Chairman, DirectorVor Biopharma Inc. (VOR) · full profile →Form 4 · filed Dec 9, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 5, 2025Grant(A)4.2M—$04.2M
Dec 5, 2025Disposed to issuer(D)4.2M—$00

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001654979-25-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML